Dr. James Leontiades
October 3rd, 2014
Dr. James (Jim) Leontiades is currently Academic Dean at the Cyprus Institute for International Management. His Business experience includes several years in the Planning Department of General Motors Overseas Operations as well as positions with consulting firms in London ...
Why is Cyprus Tourism Failing?
October 2nd, 2014
World tourism is the one industry that does not seem to have been affected by the financial crisis. Tourist arrivals to various global destinations have grown steadily. The numerous upbeat statements of the Cyprus Tourist Organization (CTO) give the ...
Contributing Authors
October 2nd, 2014
Dr Alan Waring Dr Alan Waring has 35 years’ experience in risk management. His several books include Managing Risk (1998), co-authored with Prof Ian Glendon, Practical Systems Thinking (1996) and Corporate Risk and Governance published in May 2013. He has presented numerous conference and ...
Australia 200 – Enjoys Some Support Around 5250
October 2nd, 2014
Australia 200 for Thursday, October 2, 2014 For all of September the Australia 200 Index has declined strongly from its multi-year high after running into resistance around 5650 back to enter its previously established trading range between 5400 and ...
Tax Tactics Threaten Public Funds
October 2nd, 2014
When the European Commission charged this week that Ireland’s sweetheart tax treatment of Apple amounted to an illegal corporate subsidy, the company said that it had done nothing wrong. Corporate tax strategies intended to minimize global taxes, by hook ...
Drug patents held overseas can pare makers’ tax bills
September 30th, 2014
As the Obama administration tries to stop companies from avoiding taxes by moving their headquarters overseas, the makers of some of the world’s most lucrative and expensive medicines are using another tactic to reduce their payments to the government. ...
Japan’s Daiichi Sankyo to acquire US biopharma Ambit Biosciences
September 29th, 2014
Japanese drugmaker Daiichi Sankyo Co Ltd (4568.T) has agreed to acquire U.S. biopharmaceutical company Ambit Biosciences Corp (AMBI.O) in a deal valued up to $410 million as it looks to build its presence in oncology, the companies said. The ...
Economists can’t tell Scots how to vote
September 17th, 2014
Here is the bad news if you haven’t made up your mind whether to vote for Scotland to become independent – economic analysis cannot give you the answer. That is partly because this dismal science is not capable of ...
Australia 200 – Entrenched in Previous Trading Range Below 5500
September 17th, 2014
Australia 200 for Wednesday, September 17, 2014 For the last couple of weeks the Australia 200 Index has declined from its multi-year high after running into resistance around 5650 back to enter its previously established trading range between 5400 ...
Drug maker seeks to block competitor’s inversion
September 17th, 2014
Pharmaceutical company, Endo International, which struck an inversion last year and reincorporated in Ireland, tries to stop an inversion by Auxilium Pharmaceutical, a smaller rival. Endo made on Tuesday an unsolicited offer to buy Auxilium for $28.10 a share ...
